ASCRS 2024: Enrollment begins in Canada for cell therapy trial, targeting corneal endothelial disease

At the 2024 ASCRS meeting in Boston, Massachusetts, we spoke with Greg Kunst, CEO of Aurion Biotech. He relayed the latest news from Aurion and the company's work in cell therapies for corneal endothelial disease.

Editor's note: The following transcript has been lightly edited for clarity.

Hello, I'm Greg Kunst, CEO of Aurion Biotech. We're here at the 2024 American Society of Cataract and Refractive Surgeons, and Aurion Biotech this week is talking about our novel cell therapy targeting corneal endothelial disease. We'll be presenting two papers, one on the use of our cell therapy, not only in corneal endothelial disease but in conjunction with cataract surgery. We'll also be showing a paper where, from our trial in El Salvador, where we compare the the drug, our drug as a combination drug with cells and with Rho-kinase, versus cells alone.

Additionally, we announced just this past week that we have enrolled our first patients in Canada. We're nearing full enrollment in our Phase 1/2. We expect sometime next year to be able to present that data. Stay tuned for when that that data becomes available. Thank you very much. Have a great rest of your day.